GvHD Hub

Results from the real-world ROCKreal study showed that belumosudil improved ORR at 6 months compared with best available therapy in patients with SR-cGvHD (38.7% vs 26.8%; p = 0.040). loom.ly/2x-gmaU #GvHD #MedEd #MedNews

New publication 📝 A post-hoc analysis published in the International Journal of Hematology shows higher rates of lower-GI aGvHD-FS with vedolizumab vs placebo prophylaxis in Japanese patients post allo-HSCT (94% vs 81%). Learn more: loom.ly/rYYBIVc #GvHD #aGvHD…

Did you know you can filter content on the #GvHD Hub website depending on your specific interests – whether that is by GvHD type, therapeutics, trials, or congresses? 👉 loom.ly/h0tWtwA #MedEd #gvhds

During the GvHD Hub Steering Committee Meeting, @Mohty_EBMT discussed the use of Lee Symptom Scale PRO tool in the management of cGvHD. Watch the full discussion on measurement of QoL and use of PROs tools in cGvHD here: loom.ly/sCszLFg #GvHD #MedNews #MedEd

Listen to our expert steering committee discuss how to improve measurement of QoL and use of PROs in chronic GvHD: loom.ly/zfJtjUU #GvHD #MedNews #MedEd

📝 A new study presented at #EHA2025 by @Mohty_EBMT highlights MaaT013 as a potential microbiota-based option for SR/SD GI-aGvHD, with consistent efficacy and survival across real-world and trial settings. More news: gvhdhub.com #GvHD #MedNews #MedEd

📝 A 2025 update from the NIH Consensus Conference, published in @ASTCT_Journal, recommends that implementation of community-based efforts for early identification and diagnosis of cGvHD are essential. More news: GvHDhub.com #GvHD #cGvHD #MedNews #MedEd

New publication 📝 Real-world results of MaaT013, presented by @Mohty_EBMT at #EHA2025, show 53% Day 28 GI-ORR in patients with SR/SD GI-aGvHD; most responders achieved VGPR. Learn more: loom.ly/wfMJOxw #GVHD #MedEd #MedNews

New publication 📝 A 2025 update from the NIH Consensus Conference, published in @ASTCT_Journal, highlights major progress in cGvHD prevention with PTCy in the RIC setting. Learn more: loom.ly/QaTET08 #GvHD #cGvHD #MedNews #MedEd

During the GvHD Hub Steering Committee Meeting, @NicoGagelman shared findings from a German retrospective study investigating the efficacy of ECP + ruxolitinib vs ruxolitinib alone in patients with SR-aGvHD. Watch the full discussion here: loom.ly/4tkgPLA #GvHD…

📝 Results from a phase II trial published in @BloodAdvances found that tocilizumab was associated with reduced Grade 1–4 lower GI #aGvHD incidence (p = 0.056) compared with no tocilizumab in patients with hematologic malignancies. More news: gvhdhub.com #GvHD…

Listen to our expert steering committee discuss the use of ECP + ruxolitinib to prevent cGvHD in patients with SR-aGvHD: loom.ly/U_pwt2w #GvHD #MedNews #MedEd

New publication 📝 Results from a phase II trial published in @BloodAdvances show that Grade 2–4 #aGvHD at Day 100 was comparable between patients with hematologic malignancies receiving tocilizumab vs no tocilizumab (p = 0.11). Learn more: loom.ly/cVFOcmU #GvHD…

Watch a discussion by our steering committee on QoL in GvHD, including commonly used PRO tools and the challenges integrating these into clinical practice: loom.ly/sCszLFg #GvHD #MedED #MedNews

Watch our expert steering committee discuss how to improve measurement of QoL and use of PROs in cGvHD, chaired by @Mohty_EBMT: loom.ly/sCszLFg #GvHD #MedED #MedNews

Thank you to our funders, who make it possible for us to deliver the #GvHD Hub. • Medac • Sanofi • Therakos #gvhdsm

Catch up on the latest developments in #GvHD prophylaxis from #EHA2025, with live social media coverage from the GvHD Hub. loom.ly/a6q6vgs #GvHDsm

Watch a discussion by our steering committee on the use of ECP + ruxolitinib combination, including key efficacy outcomes, in patients with SR-aGvHD: loom.ly/4tkgPLA #GvHD #MedNews #MedEd

Catch up on the latest developments in acute and chronic #GvHD from #EHA2025, with live social media coverage from the GvHD Hub. loom.ly/EatCKyc #GvHDsm #MedEd

Watch our expert steering committee discuss the use of ECP + ruxolitinib to prevent cGvHD in patients with SR-aGvHD, in response to a presentation from guest speaker @NicoGagelmann: loom.ly/4tkgPLA #GvHD #MedNews #MedEd

CONGRESS | #EHA2025 | POSTER Natalia Gemperle Ortiz presented the PHOEBUS trial exploring the potential of a full microbiota ecosystem therapy to enhance survival in alloHCT patients for the first time. Primary endpoint is OS at 12 months after randomization. Pts will receive…